What's happening in PHARMAC - Where do all the submissions go? On the trail of gemcitabine

New Zealand Medical Journal

Volumn 118, Issue 1225, 2005, Pages

  Simpson, Andrew ^a  

^a WELLINGTON HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ACCESS TO INFORMATION; ADVANCED CANCER; ARTICLE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COST UTILITY ANALYSIS; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG INFORMATION; FINANCIAL MANAGEMENT; HUMAN; INTERNET; INTERPERSONAL COMMUNICATION; LICENCE; MEDICAL DECISION MAKING; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; QUALITY ADJUSTED LIFE YEAR; SEPSIS; SURVIVAL TIME; TIME MANAGEMENT; TRANSITIONAL CELL CARCINOMA; BLADDER TUMOR; DRUG APPROVAL; ECONOMICS; NEW ZEALAND; PUBLIC HEALTH;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; DRUG APPROVAL; HUMANS; NATIONAL HEALTH PROGRAMS; NEW ZEALAND; URINARY BLADDER NEOPLASMS;

EID: 27944463625     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Von der Masse H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large randomised, multinational, multicenter, phase III study. J Clin Oncol. 2000;17:3068-77.
2. Bellmunt J, de Wit R, Albiol S, et al. New drugs and new approaches in metastatic bladder cancer. Critical Reviews in Oncology/Hematology. 2003;47:195-206.
3. Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomised comparison of cisplatin alone or in combination with Methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10:1066-73.
4. Extending access to gemcitabine in the Pharmaceutical Schedule for patients with advanced bladder cancer. PHARMAC Draft Technology assessment Report No. 66, January 2005. Released under the Official Information Act.
5. PHARMAC. New Zealand Pharmaceutical Schedule: Schedule H for Hospital Pharmaceuticals, effective 1 July 2005. Wellington: PHARMAC; 2005. Available online. URL: http://www.pharmac.govt.nz/pdf/SectionH.pdf Accessed November 2005.
6. Australian Government, Department of Health and Ageing. Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners. Canberra: Australian Government; 2005. Available online. URL: http://www1.health.gov.au/pbs/ Accessed November 2005.
7. Robinson P, von der Masse H, Bhalla S, et al. Cost-utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer. Expert Rev Pharmacoeconomics Outcomes Res. 2004;4:27-39.
8. Eli Lilly and Company (NZ) Limited. PO Box 109197, Newmarket, Auckland. URL: http://www.lilly.co.nz/
9. PHARMAC. Applications received for new investments since 1 July 2002. Wellington: PHARMAC; 2005. Available online. URL: http://www.pharmac.govt.nz/pdf/230905.pdf Accessed November 2005.